Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

David Epstein emerges at newly named Flagship Pioneering

Flagship Pioneering today announced the appointment of industry veteran David Epstein to serve in the newly created role of Executive Partner. Epstein will join as a strategic resource to the firm that systematically conceives, creates, resources and grows first-in-category ventures … Continue reading

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , | Leave a comment

Cortendo joins a rare disease crowd in Ireland

  Sweden’s Cortendo AB  has announced its intention to relocate the parent company of the Cortendo group from Sweden to Ireland. The Company is contemplating effecting such redomiciliation through an exchange offer in which Cortendo plc, a newly incorporated Irish … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , | Leave a comment

Shire goes hostile on Baxter spin-out Baxalta

Fresh from announcing that the company will acquire Foresight BioTherapeutics for $300m (here), Shire stepped up its ambitions to acquire the recently spun-out Baxalta, which went public earlier this summer (here). Shire originally approached the Baxalta Board of Directors earlier … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , | Leave a comment

Biotech M&A Continues to Climb the Curve

The trajectory of biotech M&A has been steep in 2015, so the $7.2bn acquisition of Receptos by oncology powerhouse Celgene, increases the gradient even further. This deal came out of left field, especially as commentators were still raking over the … Continue reading

Posted in M&A Finance and Funding, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

M&A Continues to Dominate the Rare Diseases Landscape

Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Roche announces acquisition of InterMune

Authored by James Sheppard The global pharmaceutical company Roche has announced it has purchased the California based, biotech, InterMune, for $8.3bn. The deal will give Roche access to a potential blockbuster drug for idiopathic pulmonary fibrosis. Roche will pay $74 … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , | Leave a comment

5 Alternative Methods for assessing the potential of a new employer

Authored by Karl Simpson Below are some ideas for the contrarians among you who might assess a new job opportunity. These escape the traditional clichés and provoke you to think about why you might seek to assess jobs in a … Continue reading

Posted in Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , | Leave a comment

Roche purchases diagnostic company IQuum

Authored by James Sheppard The global pharmaceutical giant Roche announced that it completed the purchase of Boston biotech cluster based, diagnostics company IQuum. IQuum specialise in the development of point of care diagnostics (PoC) and will be absorbed into Roche’s … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

ADC Therapeutics executives on fast track with funding and partners

Authored by James Sheppard ADC Therapeutics was launched in 2012 after Auven Therapeutics (previously known as Celtic Therapeutics) launched the company with initial funding of $50m. These funds were further added to buy Auven Therapeutics and Medimmune (part of AstraZeneca) … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Jazz Pharmaceuticals to acquire rare disease company Gentium

Authored by James Sheppard Jazz Pharmaceuticals, based in Dublin, Ireland, recently announced that it had acquired Italian based rare disease drug company Gentium in a $1bn deal. The deal will give Jazz access to Gentium’s 3 marketed products and extensive … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap